Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Ramdhanny A, Vaughn J, Epperla N. Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. Blood 2024, 144: 3745. DOI: 10.1182/blood-2024-211747.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T cell therapyT-cell therapyChimeric antigen receptorChimeric antigen receptor T-cell therapyPresence of B symptomsLarge B-cell lymphomaB-cell lymphomaOverall survivalFood and Drug AdministrationRelative survivalB symptomsApproval of CAR-T cell therapyAdvent of chimeric antigen receptorCentral nervous system lymphomaMultivariable flexible parametric survival modelNervous system lymphomaMedian Follow-UpUS Food and Drug AdministrationPopulation-based cohort studySurveillance, EpidemiologyPeriod of diagnosisUS populationPersons per yearP-value <
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply